Fuchs, Michael

The plasma lipidomic signature of nonalcoholic steatohepatitis

Puri, P., Wiest, M. M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H., Contos, M. J., Sterling, R. K., Fuchs, M., Zhou, H., et al. (2009) · Hepatology

Liver Disease Diagnosis and TreatmentMetabolomics and Mass Spectrometry Studies

Cited by 655

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy

Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE

Liver Disease and TransplantationGut microbiota and health

Cited by 430

Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension

Chalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 358

A randomized clinical trial of fecal microbiota transplant for alcohol use disorder

Bajaj, J. S., Gavis, E. A., Fagan, A., Wade, J. B., Thacker, L. R., Fuchs, M., Patel, S., Davis, B., Meador, J., Puri, P., et al. (2021) · Hepatology

Gut microbiota and healthAlcohol Consumption and Health Effects

Cited by 262

Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis

Noureddin, M., Jones, C., Alkhouri, N., Gomez, E. V., Dieterich, D. T., Rinella, M. E., Therapondos, G., Girgrah, N., Mantry, P. S., Sussman, N. L., et al. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 140

Lipotoxicity in NASH

Fuchs, M., & Sanyal, A. J. (2012) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 97

Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with rifaximin in cirrhosis: implications for the gut-liver-brain axis

Ahluwalia, V., Wade, J. B., Heuman, D. M., Hammeke, T. A., Sanyal, A. J., Sterling, R. K., Stravitz, R. T., Luketic, V., Siddiqui, M. S., Puri, P., et al. (2014) · Metabolic Brain Disease

Liver Disease and TransplantationAdvanced MRI Techniques and Applications

Cited by 92

PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis: PROMIS tools for quality of life assessment in cirrhosis

Bajaj, J. S., Thacker, L. R., Wade, J. B., Sanyal, A. J., Heuman, D. M., Sterling, R. K., Gibson, D. P., Stravitz, R. T., Puri, P., Fuchs, M., et al. (2011) · Alimentary Pharmacology & Therapeutics

Psychometric Methodologies and TestingLiver Disease and Transplantation

Cited by 83

HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients

Bajaj, J. S., Sterling, R. K., Betrapally, N. S., Nixon, D. E., Fuchs, M., Daita, K., Heuman, D. M., Sikaroodi, M., Hylemon, P. B., White, M. B., et al. (2016) · Alimentary Pharmacology & Therapeutics

Gut microbiota and healthHepatitis C virus research

Cited by 63

Patient-centered care: Key elements applicable to chronic liver disease

Verma, M., Brahmania, M., Fortune, B. E., Asrani, S. K., Fuchs, M., & Volk, M. L. (2023) · Hepatology

Patient Satisfaction in HealthcarePrimary Care and Health Outcomes

Cited by 24

Which Knee Phenotypes Exhibit the Strongest Correlation With Cartilage Degeneration?

Khury, F., Oltmanns, M., Unseld, T., Fuchs, M., Reichel, H., & Faschingbauer, M. (2024) · Clinical Orthopaedics & Related Research

Osteoarthritis Treatment and MechanismsKnee injuries and reconstruction techniques

Cited by 13